Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Harm Reduction Products for NRT Non-Responders
NCT06088862Phase 3Terminated
- Sponsor
- Rose Research Center
- Start
- Dec 2023
- Primary completion
- Apr 2024
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial (5 arms), sponsored by Rose Research Center. Primary endpoint: Change in smoke exposure for NRT non-responders at 10 weeks. Started Dec 2023; status: terminated.
Beyond the preview
Go deeper on NCT06088862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06088862.